A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT). Patients with multiple myeloma who ...
The study found no significant OS or PFS improvement with auto-HCT plus Rituxan versus Rituxan alone in MCL patients in first complete remission with undetectable MRD. Three-year OS rates were 82.1% ...
T-cell therapy has transformed the treatment landscape for patients with relapsed or refractory large B-cell lymphoma (LBCL), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results